Developer of a medical device platform designed to improve the treatment of hypervascular tumours. The company is developing novel radiopaque bland embolic and beta radiation emitting radiopaque Y-90 radioembolic agents that will help to improve targeting of tumour vascularity and tumour tissue, enabling doctors to help standardize, optimize and personalize these minimally invasive therapies.

Inaccurate data? Flag it here.

Open jobs at ABK Biomedical

Privacy policy Cookie policy